Literature DB >> 24633373

A statistical study on malignant melanoma over the past 12 years in Fukui University Hospital.

Masato Yasuta1, Suguru Sato, Sachio Kouraba, Shiro Iino, Takahiro Kiyohara.   

Abstract

BACKGROUND: The survival rate of patients with malignant melanoma is still low, and there is no established chemotherapeutic method. With the appearance of molecular targeted drugs, improvement in the survival rate can be expected. However, at present, malignant melanoma remains a disease associated with one of the poorest prognoses.
MATERIALS AND METHODS: We analyzed a total of 51 cases of malignant melanoma who were treated at the Department of Dermatology, University of Fukui from September 2001 to May 2013.
RESULTS: The survival rate was significantly lower in patients aged ≥65 years. The 5-year survival rate was 100 % for Stage 0/I, 79.59 % for Stage II, and 52 % for Stage III. The incidence of lymph node metastasis was highest in nodular melanoma, and zero in lentigo maligna melanoma. There was a significantly high risk of lymph node metastasis in the presence of ulceration. There was no association between incisional biopsy and lymph node metastasis.
CONCLUSIONS: Although the data were obtained in only one institution and the number of cases was limited in this study, the results are close to previous international data.

Entities:  

Mesh:

Year:  2014        PMID: 24633373     DOI: 10.1007/s10147-014-0683-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  6 in total

1.  Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

Authors:  John F Thompson; Seng-Jaw Soong; Charles M Balch; Jeffrey E Gershenwald; Shouluan Ding; Daniel G Coit; Keith T Flaherty; Phyllis A Gimotty; Timothy Johnson; Marcella M Johnson; Stanley P Leong; Merrick I Ross; David R Byrd; Natale Cascinelli; Alistair J Cochran; Alexander M Eggermont; Kelly M McMasters; Martin C Mihm; Donald L Morton; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy.

Authors:  Timothy M Pawlik; Merrick I Ross; Marcella M Johnson; Christopher W Schacherer; Dana M McClain; Paul F Mansfield; Jeffrey E Lee; Janice N Cormier; Jeffrey E Gershenwald
Journal:  Ann Surg Oncol       Date:  2005-06-16       Impact factor: 5.344

3.  Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.

Authors:  Lutz Kretschmer; Iris Beckmann; Kai-Martin Thoms; Christina Mitteldorf; Hans Peter Bertsch; Christine Neumann
Journal:  Ann Surg Oncol       Date:  2006-07-24       Impact factor: 5.344

4.  Regional non-nodal metastases of cutaneous melanoma.

Authors:  N Cascinelli; R Bufalino; R Marolda; F Belli; M Nava; D Galluzzo; M Santinami; A Levene
Journal:  Eur J Surg Oncol       Date:  1986-06       Impact factor: 4.424

5.  Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.

Authors:  Kazuyuki Ishihara; Toshiaki Saida; Fujio Otsuka; Naoya Yamazaki
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

6.  Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.

Authors:  Zhihong Chi; Siming Li; Xinan Sheng; Lu Si; Chuanliang Cui; Mei Han; Jun Guo
Journal:  BMC Cancer       Date:  2011-02-25       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.